GlassScriptPhysician profile
Asif Masood
NPI 1194715656
$1,894.82
in general payments reported to CMS, 2019-2025
11 companies · $78.70 in 2025
The $78.70 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $337 · 2021: $1,015 · 2022: $85.66 · 2024: $98.00 · 2025: $78.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $98.00 · Food and Beverage: $78.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $98.00 |
| Food and Beverage | $78.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,014.85 | 2021 | |
| Merck Sharp & Dohme LLC | $284.37 | 2020 | |
| Janssen Pharmaceuticals, INC | $210.56 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $98.00 | 2024 | |
| Genentech USA, INC. | $84.76 | 2019 | |
| Janssen Biotech, INC. | $56.41 | 2025 | Tecvayli, Erleada, Akeega |
| Pfizer INC. | $55.40 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $42.08 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $22.29 | 2025 | Libtayo |
| Glaxosmithkline, LLC. | $14.09 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Masood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.